DUBLIN, October 13, 2017 /PRNewswire/ --
The "Complete 2017-18 Global Cord Blood Banking Industry Report" report has been added to Research and Markets' offering.
The global cord blood banking industry has matured substantially over the past few years, creating both serious threats and novel opportunities.
Serious threats to the industry include:
- New accreditation requirements that have increased the cost structure of cord blood banks
- A decline in cord blood transplants, within the U.S. and other geographical regions
- Low rates of turnover for stored cord blood units
- Expensive cord blood transplantation procedures, costing from $200-300K each
- Difficulty with educating obstetricians about cellular therapies
- Poor press coverage in many regions worldwide, including major news outlets
Other uncontrollable factors that could threaten the industry include: new legislation, changes in transplant reimbursement, continually evolving accreditation requirements, the potential for competitive approaches to be shown as more optimal, patent challenges for processing or transplant technologies, changes in public perception of private vs. public banking, shift in policy recommendations by influential medical organizations, and changes in government support.
Marketing pressures are also impacting the industry, with the term cord blood becoming one of the 20 most expensive search terms on Google, reaching more than $20 per click for global search traffic and over $70 per click for U.S. search traffic.
However, there are also emerging opportunities, including:
- The potential to expand market size through increasing public awareness
- New clinical trial data supporting applications for hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue
- Improving public perception toward stem cell therapies
- Substantial deal-making within the industry, including mergers, acquisitions, and funding rounds
- The potential for cross-organizational collaboration through formation of Cord Blood Industry Associations (occurring in within U.S. and South America)
- A trend toward diversification within the industry, with cord blood banks effectively becoming stem cell banks through the storage of cord blood, cord tissue, and in some cases, placental tissue, amniotic fluid, and more
Within this rapidly evolving ecosystem, those who choose to commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage.
Key Report Findings
The report is designed to guide the decision-making of cord blood banks worldwide, as well as to advise private, corporate, and institutional investors entering into this market.
The report analyzes the types of investments being made within the cord blood marketplace, including investments made by:
- ABS Capital Partners & HLM Management
- KKR & Company
- Bay City Capital
- GTCR, LLC
- Excalibur
Key findings contained within the report include:
- Market size determinations for the global cord blood market
- Trend rate data for umbilical cord blood grants, patents, and scientific publications
- Clinical trial rate analysis, including comparison of cord blood vs. cord tissue frequency
- Rates of global cord blood storage (units per year)
- Rates of global cord blood transplant (units per year)
- Current and future conditions treatable with cord blood
- Probability of requiring a stem cell transplant by age
- Trends in medical opinions of cord blood banking
- Changes in legislative support for cord blood banking
- Investors impacting the global cord blood banking marketplace
- Competitive environment analysis, including assessment of cord blood market leaders
- Influential alliances within the cord blood industry
- SWOT analysis for global cord blood industry (Strengths, Weaknesses, Opportunities, Threats)
- Crucial trends and unmet market needs
Companies Mentioned
- ABS Capital Partners & HLM Management
- AllCells
- AMAG Pharmaceuticals
- AlphaCord
- Americord
- Bay City Capital
- BioEden
- Biocell Center
- Biosafe
- CariCord
- Cell Care (Australia)
- Cesca Therapeutics
- China Cord Blood Corporation (CCBC)
- CorCell
- Cord Blood Registry (CBR)
- Cordlife
- Core23 BioBank
- Crioestaminal
- Cryo-Cell International
- Cryoholdco
- Cryolife
- CryoSave
- Excalibur
- FamilyCord
- Fate Therapeutics
- Future Health Biobank
- Gamida Cell Ltd.
- GeneCell International
- Genesis Bank
- GTCR, LLC
- HealthBaby
- HealthBanks Biotech Company Ltd
- Human Longevity Inc.
- Insception Lifebank
- KKR & Company
- LifebankUSA
- LifeCell International
- Lonza
- MAZE
- MiracleCord
- Nanjing Cenbest
- Natera, Inc. (EverCordTM)
- New England Cord Blood Bank
- National Cord Blood Program (NCBP) at the New York Blood Center
- Nohla Therapeutics
- Novartis
- PacifiCord
- PerkinElmer
- Pluristem Therapeutics
- Precious Cells Group
- PromoCells
- ReeLabs
- Sanpower Group
- Shandong Cord Blood Bank
- Stem Cell Cryobank
- STEMCELL Technologies
- StemCyte
- Thermo Fisher Scientific
- Transcell Biologics Pvt Ltd,
- VAULT SC Inc.
- ViaCord
- Vita34 AG
For more information about this report visit https://www.researchandmarkets.com/research/xqbmqt/complete_201718
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
